Status:
COMPLETED
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost
Lead Sponsor:
CHA University
Collaborating Sponsors:
Samil Pharmaceutical Co., Ltd.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-...
Detailed Description
Not provided
Eligibility Criteria
Inclusion
- IOP \>/= 15mmHg and \< 40 mmHg in each eye using Goldmann applanation tonometry at visit 2
- Written consent voluntarily to participate in this clinical trial
Exclusion
- Patients with closed-angle, congenital glaucoma or secondary glaucoma caused by steroid drugs, etc.
- best-corrected visual acuity 20/80 or less
- Patients who have ongoing medical history of ocular inflammation
- central corneal thickness is not in between 470um and 591um.
- Patients who have received lacrimal duct procedure within the last 3 months or who have plans to have it.
- pregnant or nursing women
Key Trial Info
Start Date :
April 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2020
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04743622
Start Date
April 30 2019
End Date
September 13 2020
Last Update
February 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA University Bundang Medical Center
Seongnam, Bundang-gu, South Korea, 13497